Trial Profile

Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Finding Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Vadadustat in Japanese Subjects With Anemia Secondary to Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 31 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

31 Oct 2025 According to a Tanabe Pharma Corporation media release, Mitsubishi Tanabe Pharma Corporation is now called Tanabe Pharma Corporation.
28 Jul 2020 Results assessing safety and efficacy of daily oral vadadustat in two clinical studies: NDD-CKD (NCT03054350) and DD-CKD (NCT03054350) in Non-dialysis dependent or dialysis-dependent Chronic kidney disorder induced anemia in Japanese participants published in the Nephrology Dialysis Transplantation
04 Jan 2018 Status changed from active, no longer recruiting to completed according to an Akebia Therapeutics media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com